How venom composition, protein identification and functional testing inform antivenom research.
Venom is a complex and variable mixture of biologically active molecules. Discover how proteomics helps researchers connect toxin composition with biological effects and antivenom performance.
Snake venom is not a single substance. It is a complex biological mixture whose composition can differ between species and, in some cases, among populations of the same species. Understanding that variation is central to research on venom effects and the suitability of antivenoms.
Snakebite envenoming remains a major public-health concern in many tropical and subtropical regions. The World Health Organization’s 2026 fact sheet estimates that 5.4 million people are bitten by snakes each year, with 1.8–2.7 million cases of envenoming. The burden is concentrated in settings where people may have limited access to timely and appropriate healthcare. Safe, effective antivenom is a cornerstone of treatment, but the quality and regional appropriateness of available products matter.
What makes venom biologically complex?
Venoms contain mixtures of proteins, peptides and other components. Depending on the species, important toxin families can include phospholipases A2, snake-venom metalloproteinases, serine proteases and three-finger toxins. These families can contribute to different effects, such as tissue injury, disturbances in blood coagulation, muscle damage or neurotoxicity. The exact composition and relative abundance of toxins are not identical across all snakes.
That variation creates a practical research question: does an antivenom raised against one venom preparation recognise and neutralise the clinically important components of venoms encountered in another geographic region? A product’s performance cannot safely be assumed to be identical across all species and locations.
What does venom proteomics tell us?
Proteomics is the large-scale study of proteins in a biological sample. In venom research, proteomic approaches—often including liquid chromatography coupled with tandem mass spectrometry (LC–MS/MS)—help researchers identify toxin families and compare their relative representation in different venom samples.
These data can reveal which toxin groups dominate a sample, which components vary across populations and which proteins deserve closer functional investigation. They can also be compared with transcriptomic information, biological activity measurements and clinical or epidemiological observations. No single dataset answers every question, but integrating different evidence types can build a more informative picture of venom biology.
From protein identification to biological function
Identifying a protein is not the same as demonstrating what it does. A careful research programme therefore links molecular characterisation with fit-for-purpose functional experiments. Depending on the research question, investigators may examine enzymatic activity, effects on relevant biological systems, immunoreactivity and the ability of an antivenom to neutralise specific toxic activities.
It is also important to distinguish antibody binding from functional neutralisation. An antivenom may recognise a toxin without fully blocking its biological effect. Comprehensive evaluation therefore considers the relevant toxin activities and the standards appropriate to the intended market and clinical context.
Why geography matters for antivenom research
Studies of Asian venomous snakes have documented variation in toxin profiles between species and geographic populations. Such differences can influence the extent to which an antivenom raised using one venom mixture cross-reacts with another. This is one reason why representative venom sampling, well-described reference materials and transparent testing are important for antivenom development and assessment.
Research can contribute by improving knowledge of medically important local species, characterising relevant venom components and producing evidence that helps researchers and regulators evaluate whether antivenoms are appropriate for the populations they are intended to serve. The WHO has repeatedly highlighted the importance of quality, regulatory oversight and access to safe and effective antivenoms.
The Bangladesh research context
MBPSL identifies the biochemical characterisation of venom from venomous snakes of Bangladesh, evaluation of antivenom efficacy and the identification of physiologically interesting proteins or peptides as part of its research programme. This area brings molecular biology and protein science into direct contact with a significant public-health challenge.
For students entering the field, the topic offers opportunities to understand how protein chemistry, mass spectrometry, immunology, functional assays and public-health priorities can inform one another. It also highlights the importance of appropriate institutional oversight, trained personnel and established safety systems for all work involving venomous animals or venom samples.
Further reading
- World Health Organization (2026). Snakebite envenoming. WHO fact sheet.
- Ding, S. M. and Yap, M. K. K. (2024). Deciphering toxico-proteomics of Asiatic medically significant venomous snake species: A systematic review and interactive data dashboard. Toxicon article.
- Wang, J.-L. (2024). Antivenom treatment for snakebite envenoming. Nature Reviews Disease Primers.
- MBPSL. Research facilities and publications. View the laboratory’s research areas.
This is a research explainer, not advice for snakebite first aid or clinical management. Suspected snakebite requires urgent medical attention.
